FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1551666838> ?p ?o ?g. }

• W1551666838 endingPage "17403" @default.
• W1551666838 startingPage "17391" @default.
• W1551666838 abstract "Cancer treatment alters microRNA (miRNA) expression, revealing potential therapeutic targets (oncotarget). Here we treated pancreatic cancer (ASPC-1) cells with either recombinant human endostatin (rh-endostatin) or gemcitabine. Then high-throughput sequencing assay was performed to screen for altered miRNAs. Both treatments decreased levels of MiR-19a. We found that miR-19a stimulated cell proliferation, migration, invasion in vitro and tumor growth in vivo. High levels of miR-19a correlated with poor prognosis in patients. Ras homolog family member B (RHOB) was identified as a direct target of miR-19a. Furthermore, RHOB was down-regulated in human pancreatic cancer samples. Restoration of RHOB induced apoptosis, inhibited proliferation and migration of ASPC-1 cells. SP-1 was identified as an upstream transcription factor of miR-19a gene, promoting miR-19a transcription. Rh-endostatin decreased miR-19a expression by down-regulating SP-1. These findings suggest that miR-19a is a potential therapeutic target in pancreatic cancer." @default.
• W1551666838 created "2016-06-24" @default.
• W1551666838 creator A5000384047 @default.
• W1551666838 creator A5007542543 @default.
• W1551666838 creator A5009753049 @default.
• W1551666838 creator A5021097559 @default.
• W1551666838 creator A5035071933 @default.
• W1551666838 creator A5038851564 @default.
• W1551666838 creator A5044367029 @default.
• W1551666838 creator A5045599932 @default.
• W1551666838 creator A5052343893 @default.
• W1551666838 creator A5063311758 @default.
• W1551666838 creator A5076185144 @default.
• W1551666838 creator A5080003280 @default.
• W1551666838 creator A5080616163 @default.
• W1551666838 creator A5083210325 @default.
• W1551666838 date "2015-05-25" @default.
• W1551666838 modified "2023-10-12" @default.
• W1551666838 title "Sp1-driven up-regulation of miR-19a decreases RHOB and promotes pancreatic cancer" @default.
• W1551666838 cites W14098964 @default.
• W1551666838 cites W1530269273 @default.
• W1551666838 cites W1863975878 @default.
• W1551666838 cites W1970720053 @default.
• W1551666838 cites W1976797572 @default.
• W1551666838 cites W1978465526 @default.
• W1551666838 cites W1981114090 @default.
• W1551666838 cites W1982875680 @default.
• W1551666838 cites W1983722200 @default.
• W1551666838 cites W1993389061 @default.
• W1551666838 cites W1999328907 @default.
• W1551666838 cites W2005772593 @default.
• W1551666838 cites W2014442719 @default.
• W1551666838 cites W2019965037 @default.
• W1551666838 cites W2027598316 @default.
• W1551666838 cites W2032845340 @default.
• W1551666838 cites W2041095872 @default.
• W1551666838 cites W2046375626 @default.
• W1551666838 cites W2058081991 @default.
• W1551666838 cites W2060041427 @default.
• W1551666838 cites W2064137209 @default.
• W1551666838 cites W2070839404 @default.
• W1551666838 cites W2074231269 @default.
• W1551666838 cites W2078950380 @default.
• W1551666838 cites W2090961656 @default.
• W1551666838 cites W2095630332 @default.
• W1551666838 cites W2095802158 @default.
• W1551666838 cites W2095892427 @default.
• W1551666838 cites W2096751411 @default.
• W1551666838 cites W2101259861 @default.
• W1551666838 cites W2101879774 @default.
• W1551666838 cites W2106787323 @default.
• W1551666838 cites W2119259252 @default.
• W1551666838 cites W2121058679 @default.
• W1551666838 cites W2125246661 @default.
• W1551666838 cites W2131798870 @default.
• W1551666838 cites W2134644611 @default.
• W1551666838 cites W2138039462 @default.
• W1551666838 cites W2145381652 @default.
• W1551666838 cites W2149296979 @default.
• W1551666838 cites W2150122317 @default.
• W1551666838 cites W2151619744 @default.
• W1551666838 cites W2154932881 @default.
• W1551666838 cites W2157609508 @default.
• W1551666838 cites W2157642143 @default.
• W1551666838 cites W2158436034 @default.
• W1551666838 cites W2162961035 @default.
• W1551666838 cites W2166094737 @default.
• W1551666838 cites W2166724224 @default.
• W1551666838 cites W2169771936 @default.
• W1551666838 cites W2396706141 @default.
• W1551666838 doi "https://doi.org/10.18632/oncotarget.3975" @default.
• W1551666838 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4627316" @default.
• W1551666838 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26041879" @default.
• W1551666838 hasPublicationYear "2015" @default.
• W1551666838 type Work @default.
• W1551666838 sameAs 1551666838 @default.
• W1551666838 citedByCount "46" @default.
• W1551666838 countsByYear W15516668382016 @default.
• W1551666838 countsByYear W15516668382017 @default.
• W1551666838 countsByYear W15516668382018 @default.
• W1551666838 countsByYear W15516668382019 @default.
• W1551666838 countsByYear W15516668382020 @default.
• W1551666838 countsByYear W15516668382021 @default.
• W1551666838 countsByYear W15516668382022 @default.
• W1551666838 countsByYear W15516668382023 @default.
• W1551666838 crossrefType "journal-article" @default.
• W1551666838 hasAuthorship W1551666838A5000384047 @default.
• W1551666838 hasAuthorship W1551666838A5007542543 @default.
• W1551666838 hasAuthorship W1551666838A5009753049 @default.
• W1551666838 hasAuthorship W1551666838A5021097559 @default.
• W1551666838 hasAuthorship W1551666838A5035071933 @default.
• W1551666838 hasAuthorship W1551666838A5038851564 @default.
• W1551666838 hasAuthorship W1551666838A5044367029 @default.
• W1551666838 hasAuthorship W1551666838A5045599932 @default.
• W1551666838 hasAuthorship W1551666838A5052343893 @default.
• W1551666838 hasAuthorship W1551666838A5063311758 @default.
• W1551666838 hasAuthorship W1551666838A5076185144 @default.
• W1551666838 hasAuthorship W1551666838A5080003280 @default.

• next